NSABP Members' Area
  Password Protected - Access
  Limited to NSABP Participating
  Institutions Only


NSABP Foundation, Inc.



General NSABP Information
  Financial Conflicts of
     Interest Policy
  Coalition Comment:
     Reconfiguration
  IOM Report Group Comment
  Contact the NSABP
  Pathology Section
  Future Meetings
  NSABP Newsletters
  Media Info on STAR
  Employment

Clinical Trials Information
  Clinical Trials Overview
  Protocol Chart
  Never Say Lost

Treatment Trials Information
  Protocol B-43
  Protocol B-47
  Protocol B-51

Prevention Trials Information
  Protocol P-1 - BCPT
  Protocol P-2 - STAR
  Protocol P-5
  BreastCancerPrevention.com

Scientific Publications

Related Web Sites



Medical Search Engines



To report problems, ask
questions or make comments,
please send e-mail to:
Webmaster@nsabp.pitt.edu

NSABP Clinical Trials Overview


Protocol B-16
A Three-Arm Clinical Trial Comparing Tamoxifen Alone with L-PAM, 5-FU, Adriamycin and Tamoxifen or with Short, Intensive Adriamycin-Cyclophosphamide and Tamoxifen in Positive-Node Patients Having the Following Age and Receptor Criteria:
50-59 Years - PR = 10 fmol or more, regardless of ER
60-70 Years - All Patients


Specific Aims
To determine, in patients with histologically positive axillary nodes who are classified as tamoxifen-responsive, whether tamoxifen alone is as effective as (1) PAF + tamoxifen, or (2) short-course, intensive chemotherapy with AC + tamoxifen, with respect to disease-free survival and survival. The efficacy of ACT relative to PAFT will also be evaluated.